Clinical Development
Pipeline /
Clinical Trials
Clinical Development
Pipeline /
Clinical Trials
Advancing our proprietary technology platform
FOCUSED PIPELINE WITH STRONG GROWTH POTENTIAL AND THE POWER TO IMPROVE PATIENTS’ LIVES
We are driving our proprietary technology platform forward, with a focused pipeline that holds immense growth potential and the capability to enhance the lives of patients. Our innovative technology leverages the regenerative properties of a patient’s own skin to address various skin-related conditions. With robust clinical evidence and peer-reviewed publications supporting our approach, our late-stage pipeline concentrates on utilizing the RECELL® System to prepare and administer Spray-On Skin™ Cells for treating injuries and skin defects.
WOUND HEALING
thermal burn wounds | full-thickness skin defects
REPIGMENTATION
vitiligo patients
Discovery and Concept
Preclinical Research
Clinical Study
Regulatory Submission
Regulatory Approved
Commercialization
WOUND HEALING
THERMAL BURNS, PARTIAL THICKNESS
THERMAL BURNS, FULL-THICKNESS
FULL-THICKNESS SKIN DEFECTS:
Traumatic Wounds
Surgical Wounds
Surgical Excision for Cancer
REPIGMENTATION
VITILIGO
Discovery and Concept
Preclinical Research
Clinical Study
Regulatory Submission
Regulatory Approved
Commercialization
WOUND HEALING
ACUTE BURNS
Current clinical trials
Repigmentation of stable vitiligo lesions
Click here for more information about eligibilty and enrollment in AVITA Medical’s Vitiligo Clinical Study.
The TONE Study: A Prospective Post-Market Clinical Study Investigating Reigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells
Study: NCT05971381 on clinicaltrials.gov
RECELL provides point-of-care regenerative therapy for thermal burn wounds and full-thickness skin defects.